OptiNose Dives To New Low, ReWalk Tumbles, SYN Down 60% This Month

(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. OptiNose Inc. (OPTN)

Optinose is a specialty pharmaceutical company developing products for patients treated by ear, nose, and throat (ENT) or allergy specialists.

Lost 28.97% to close Tuesday's (Aug 14) trading at $13.85.

News: The Company reported financial results for the second quarter ended June 30, 2018.

Net loss attributable to common stockholders for the recent second quarter was $24.6 million or $0.64 per share on revenue of $1.3 million. Revenue was generated through the sales of XHANCE, a prescription medicine used to treat nasal polyps in adults.

Net loss attributable to common stockholders for the second quarter of 2017 was $12.8 million or $3.16 per share on nil revenue.

2. Xenetic Biosciences Inc. (XBIO)

Xenetic Bio is a clinical-stage biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics.

Lost 14.95% close Tuesday's trading at $3.47.

News: No news

Clinical Trials & Near-term Catalysts:

-- The lead program is XBIO-101, under phase II study for treatment of progesterone resistant endometrial cancer. Preliminary data from this study is expected this year. -- A biomarker study with XBIO-101 for triple negative breast cancer is also being planned.

3. ReWalk Robotics Ltd. (RWLK)

Rewalk manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.

Lost 13.89% close Tuesday's trading at $0.93.

News: The Company reported disappointing financial results for the quarter ended June 30, 2018.

Net loss was $5.8 million or $0.18 per share for the second quarter of 2018 on revenue of $1.8 million. Analysts polled by Thomson Reuters expected a loss of $0.16 per share on revenue of $1.95 million.

The net loss was $6.3 million or $0.37 per share on revenue of $2 million in the second quarter of 2017.

Looking ahead, the Company now expects revenues for full-year 2018 to be at the lower end of its previously announced range of $9.0 to $11.0 million while the analysts' consensus estimate is $9.42 million.

4. Protagonist Therapeutics Inc. (PTGX)

Protagonist is a clinical stage biopharmaceutical company developing novel peptide-based drugs.

Lost 13.26% to close Tuesday's trading at $8.31. The stock has given back most of its returns of last week.

News: No news

Recent event:

On August 6, shares of Protagonist rose more than 58%, following an independent blinded re-analysis of the Company's phase II study of oral alpha-4-beta-7 integrin antagonist PTG-100 for the treatment of patients with ulcerative colitis, dubbed PROPEL. The re-analysis provided signals of clinical efficacy and it supported further development of PTG-100.

Near-term Catalysts:

-- The Company plans to discuss the next steps in advancing the clinical development of PTG-100 with the FDA and other global regulatory authorities in the second half of 2018. -- The U.S. IND filing for PTG-200 by partner Janssen Biotech that will support the initiation of a global Phase 2 study in Crohn's disease is expected in the fourth quarter of 2018. This IND filing would trigger a milestone payment of $25 million to Protagonist from Janssen. -- In the second quarter of 2018, the Company filed a U.S. IND for PTG-300 to support the initiation of a global Phase 2 trial in patients with beta-thalassemia.

5. Synthetic Biologics Inc. (SYN)

Synthetic Biologics is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients.

Lost 12.23% to close Tuesday's trading at $2.80.

News: No news

Recent event:

On August 13, the Company's common stock began trading on a 1:35 reverse stock split-adjusted basis.

Near-term Catalysts:

-- An End-of-Phase 2 meeting with the FDA to solidify the remaining elements of the planned phase III trial of SYN-004 for the prevention of C. difficile infection is anticipated in the third quarter of 2018. -- Initiate phase III trial of SYN-004 in 2H 2019.